Director / Senior Director, Drug Product Development and Manufacturing (Biologics)

Overview

Director / Senior Director, Drug Product Development and Manufacturing (Biologics) – Waltham, Massachusetts, United States. Hybrid work arrangement; candidates will be in-office 3 days / week.

About Us

Oruka Therapeutics (Nasdaq : ORKA) is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka’s mission is to offer patients suffering from chronic skin diseases like plaque psoriasis the greatest possible freedom from their condition by achieving high rates of complete disease clearance with dosing as infrequently as once or twice per year. Oruka is advancing a proprietary portfolio of potentially best-in-class antibodies that were engineered by Paragon Therapeutics and target the core mechanisms underlying plaque psoriasis and other dermatologic and inflammatory diseases. For more information, visit www.orukatx.com

Role Overview

We are seeking an experienced and motivated candidate to manage aseptic drug product development and manufacturing in support of early-to-late-stage manufacturing campaigns. In this role, you will be responsible for drug product process development, technology transfer and manufacturing campaigns at the external CDMO partners. You are an ideal candidate for this role if you have experience with drug product process development, aseptic unit operations, and relevant fill finish equipment utilized for biologics manufacturing. In this role, you will have the opportunity to foster strong collaboration, communication, and problem solving to meet key program and corporate objectives. This is a highly visible role and a pivotal addition to our growing organization where you will play an integral role in supporting multiple campaigns in support of generating supplies for clinical trials across US, Canada and EU.

Key Responsibilities

• Lead liquid drug product process development, technology transfer, and GMP aseptic manufacturing at external CDMO partners
• Serve as an aseptic fill finish subject matter expert and support manufacturing process readiness, sampling plans, and in-process control strategy for drug products in vials and pre-filled syringes
• Liaise with drug product formulation and analytical SMEs to develop robust formulations, processes, methods and unit operations in support of GMP manufacturing of high concentration biologic drug products
• Lead and support gap analysis, equipment and raw material risk assessment, filter validation studies, in-use compatibility analysis, transportation, and E&L assessment in a phase appropriate manner
• Serve as person-in-plant (PIP) during drug product manufacturing campaigns
• Liaise with stakeholders to support timely approval and execution of SOPs, batch records, lot release, retests, in-process sampling plans, stability protocols / reports, retains, change controls, deviations, OOS / OOT investigations, CAPAs and campaign reports
• Ensure stakeholders such as analytical, formulation, clinical supply chain, quality and PM teams are aligned with overall drug product timelines
• Facilitate critical cross functional decisions within the CMC team while keeping program level stakeholders informed at regular interval
• Collaborate with drug substance manufacturing and clinical supply chain stakeholders ensuring robust clinical supply forecasts
• Develop road map for late-stage process development, process characterization, and PPQ campaigns
• Assist in the diligence process to select clinical and commercial CDMO vendors
• Track internal and external manufacturing deliverables and adapt to changing priorities keeping corporate CMC objectives at the forefront
• Foster a culture of collaboration, communication, critical thinking, innovation, and continuous improvement
• 20-25% travel in support of diligence and campaign execution at CDMOs

Qualifications

Compensation

What We Offer

Equal Opportunity

Oruka Therapeutics is an equal opportunity employer. We do not discriminate on the basis of any protected status. Voluntary self-identification is requested for EEO reporting; participation is voluntary and confidential.

#J-18808-Ljbffr